172 related articles for article (PubMed ID: 36592144)
21. Lung adenocarcinoma and anti-transcriptional intermediary factor 1-gamma positive dermatomyositis complicated with spontaneous oesophageal rupture.
Saraya T; Tamura M; Kasuga K; Fujiwara M; Takizawa H
Respirol Case Rep; 2019 Apr; 7(3):e00403. PubMed ID: 30766682
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of clinical and immunological features between clinically amyopathic dermatomyositis and typical dermatomyositis].
Gan YZ; Li YH; Zhang LH; Ma L; He WW; Jin YB; An Y; Li ZG; Ye H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):1001-1008. PubMed ID: 33331305
[TBL] [Abstract][Full Text] [Related]
23. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
Muro Y; Ishikawa A; Sugiura K; Akiyama M
Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
[TBL] [Abstract][Full Text] [Related]
24. Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study.
Hida A; Yamashita T; Hosono Y; Inoue M; Kaida K; Kadoya M; Miwa Y; Yajima N; Maezawa R; Arai S; Kurasawa K; Ito K; Shimada H; Iwanami T; Sonoo M; Hatanaka Y; Murayama S; Uchibori A; Chiba A; Aizawa H; Momoo T; Nakae Y; Sakurai Y; Shiio Y; Hashida H; Yoshizawa T; Sakiyama Y; Oda A; Inoue K; Takeuchi S; Iwata NK; Date H; Masuda N; Mikata T; Motoyoshi Y; Uesaka Y; Maeda MH; Nakashima R; Tsuji S; Kwak S; Mimori T; Shimizu J
Neurology; 2016 Jul; 87(3):299-308. PubMed ID: 27343066
[TBL] [Abstract][Full Text] [Related]
25. Trichoscopic, oral, and periungual fold findings as activity and damage markers in dermatomyositis patients and their correlation with myositis antibodies.
Salgueiro C; Poblete MJ; Robles-Silva C; Abarzúa Á; Vera-Kellet C
Arch Dermatol Res; 2023 Aug; 315(6):1603-1613. PubMed ID: 36757439
[TBL] [Abstract][Full Text] [Related]
26. Autoantibodies Recognizing Specificity Protein 4 Co-occur With Anti-Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis.
Sherman MA; Pak K; Pinal-Fernandez I; Flegel WA; Targoff IN; Miller FW; Rider LG; Mammen AL;
Arthritis Rheumatol; 2023 Sep; 75(9):1668-1677. PubMed ID: 36996276
[TBL] [Abstract][Full Text] [Related]
27. Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital.
Suga T; Oiwa H; Ishida M; Iwamoto Y
Clin Rheumatol; 2022 Sep; 41(9):2803-2808. PubMed ID: 35399148
[TBL] [Abstract][Full Text] [Related]
28. ELISA, protein immunoprecipitation and line blot assays for anti-TIF1-gamma autoantibody detection in cancer-associated dermatomyositis.
Selickaja S; Galindo-Feria AS; Dani L; Mimori T; Rönnelid J; Holmqvist M; Lundberg IE; Venalis P
Rheumatology (Oxford); 2022 Nov; 61(12):4991-4996. PubMed ID: 35579337
[TBL] [Abstract][Full Text] [Related]
29. Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.
Muro Y; Sugiura K; Akiyama M
Clin Rev Allergy Immunol; 2016 Dec; 51(3):293-302. PubMed ID: 26100618
[TBL] [Abstract][Full Text] [Related]
30. Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature.
Ono R; Kumagae T; Igasaki M; Murata T; Yoshizawa M; Kitagawa I
J Med Case Rep; 2021 Mar; 15(1):142. PubMed ID: 33745453
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of clinical characteristics, work-up, treatment, and association to malignancy in dermatomyositis between two tertiary skin centers in the USA and Singapore.
Yosipovitch G; Tan A; LoSicco K; Manabat CG; Kannagra A; Carroll C; Chan YH; Ng P; Jorizzo J
Int J Dermatol; 2013 Jul; 52(7):813-9. PubMed ID: 22835263
[TBL] [Abstract][Full Text] [Related]
32. SCLC, Paraneoplastic Dermatomyositis, Positive Transcription Intermediary Factor 1-γ, and Point Mutation in the Transcription Intermediary Factor 1-γ Coding Gene: A Case Report.
Arnon J; Elia A; Nevo Y; Lossos A; Nechushtan H
JTO Clin Res Rep; 2021 Sep; 2(9):100217. PubMed ID: 34590056
[TBL] [Abstract][Full Text] [Related]
33. Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
De Vooght J; Vulsteke JB; De Haes P; Bossuyt X; Lories R; De Langhe E
Rheumatology (Oxford); 2020 Mar; 59(3):469-477. PubMed ID: 31883334
[TBL] [Abstract][Full Text] [Related]
34. A case of juvenile amyopathic dermatomyositis with anti-transcription intermediary factor 1-α antibody showing negative anti-TIF1-γ ELISA results: Comment on "Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody".
Koizumi H; Muro Y; Imai S; Yamashita Y; Ogawa-Momohara M; Takeichi T; Murakami M; Mitsuma T; Akiyama M
J Dermatol; 2023 Jan; 50(1):e39-e40. PubMed ID: 36176040
[No Abstract] [Full Text] [Related]
35. Paraneoplastic Anti-Tif1-gamma Autoantibody-positive Dermatomyositis as Clinical Presentation of Hepatocellular Carcinoma Recurrence.
Ferronato M; Lalanne C; Quarneti C; Cevolani M; Ricci C; Granito A; Muratori L; Lenzi M
J Clin Transl Hepatol; 2023 Feb; 11(1):253-259. PubMed ID: 36406323
[TBL] [Abstract][Full Text] [Related]
36. Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
Sherman MA; Yang Q; Gutierrez-Alamillo L; Pak K; Flegel WA; Mammen AL; Rider LG; Casciola-Rosen LA;
Arthritis Rheumatol; 2024 Apr; 76(4):631-637. PubMed ID: 38059274
[TBL] [Abstract][Full Text] [Related]
37. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
Kim Y; Park D; Choi SY; Chung C
Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
[TBL] [Abstract][Full Text] [Related]
38. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
[No Abstract] [Full Text] [Related]
39. [Clinical and immunological characteristics of myositis complicated with thromboembolism].
Zhu FY; Xing XY; Tang XF; Li YM; Shao M; Zhang XW; Li YH; Sun XL; He J
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 52(6):995-1000. PubMed ID: 33331304
[TBL] [Abstract][Full Text] [Related]
40. Autoantibody to transcriptional intermediary factor-1β as a myositis-specific antibody: clinical correlation with clinically amyopathic dermatomyositis or dermatomyositis with mild myopathy.
Ueda-Hayakawa I; Hamaguchi Y; Okiyama N; Motegi S; Yamaoka T; Miyake S; Higashi A; Okamoto H; Takehara K; Fujimoto M
Br J Dermatol; 2019 Apr; 180(4):881-887. PubMed ID: 30120913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]